Pharmaceutical company GlaxoSmithKline (GSK) is to reveal previously confidential data on thousands of potential anti-malaria compounds.
In addition to this, the company is to pump millions into an 'Open Lab' for independent research teams.
The company has 13,500 molecules which have been tested against the parasite which causes malaria.
One expert said more sharing of data could trigger advances like those that came from the human genome project.
The way in which pharmaceutical firms guard the secrets of their drugs and research has long been cited as an obstacle to disease research.
The research community can start to build up a public repository of knowledge that should be as powerful as the human genome databases
Dr Timothy Wells, Medicines for Malaria Venture
The latest announcement by GSK chief executive Andrew Witty, follows an earlier decision to set up a "patent pool" where information about patented drugs could be shared.
In a speech in New York, he said that it was important to "earn the trust" of society.
"The measures we have announced today are characterised by a determination to be more flexible, open and willing to learn.
"GSK has the capability to make a difference and a genuine appetite to change the landscape of healthcare for the world's poorest people."
Millions scanned
The data in question is the result of a year's effort by GSK scientists to study a disease which still claims almost a million lives a year, mainly in sub-Saharan Africa.
The company holds a "library" of millions of different molecules, and each of these was tested against the Plasmodium parasite which causes malaria.
The result was 13,500 which appeared to have an effect on it, although extensive further research would be needed to narrow down this list into those most likely to succeed as new drugs.
Dr Timothy Wells, Chief Scientific Officer of the Medicines for Malaria Venture, which has worked with GSK on the project, said it had the potential to "dramatically alter" the way the world approached malaria research.
"By sharing the data, the research community can start to build up a public repository of knowledge that should be as powerful as the human genome databases and could set a new trend to revolutionise the urgent search for new medicines to tackle malaria."
Dr Mallika Kaviratne, from the Malaria Consortium, a not-for-profit organisation, said it could boost access to medicines for developing countries, as resistance to existing drugs was an important issue.
She added: "The release of 13,500 molecules made to the public is very important - we have nothing else in the pipeline - and new drugs need to be developed, but they're expensive."
Source: BBC
DISCLAIMER: The Views, Comments, Opinions, Contributions and Statements made by Readers and Contributors on this platform do not necessarily represent the views or policy of Multimedia Group Limited.
Tags:
Latest Stories
-
Betway Africa offers a once-in-a-lifetime ‘Play-on-the-Pitch’ experience at Emirates Stadium
9 mins -
School Feeding Programme: Bono East NIB seizes smuggled rice, arrest driver
30 mins -
Dr. Razak Opoku: Despite challenges, facts and data still prove NPP is better manager of the economy than NDC
38 mins -
Seidu Agongo: On December 7, it must be peace over power
46 mins -
2024 Election will take place on December 7; ignore misleading claims – EC
48 mins -
GPL 2024/25: Asante Kotoko bounce back with win over Aduana FC
1 hour -
GPL 2024/25: Gold Stars beat Vision FC to retain top spot
2 hours -
Ebo Whyte returns with ‘The 4Play’
2 hours -
2024/25 Ghana League: Heart of Lions sink Legon Cities to go third
3 hours -
Bright Simons: DBG, Ghana’s top development bank, goes for the jugular
3 hours -
Governance and Entrepreneurship consultant demands global support for Africa’s young farmers
3 hours -
Ghanaians reminded to prioritise regular health check-ups
3 hours -
Salah brace sends Liverpool 8 points clear
4 hours -
Leicester City sack manager Steve Cooper
4 hours -
Akwasi Sarpong wins AIBs 2024 Award for BBC OS coverage of Israeli hostage release
4 hours